L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés


Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du (Lipstic)


Action : Laboratoires d'excellence


N° de convention : 11-LABX-0021

Informations générales

  • Référence projet : 11-LABX-0021
  • RST : Laurent LAGROST
  • Etablissement Coordinateur : FCS Bourgogne Franche Comté
  • Région du projet : Bourgogne-Franche-Comté
  • Discipline : 5 - Bio Med
  • Aide allouée : 6 004 550 €
  • Date de début du projet : 01/03/2012
  • Date de fin du projet : 31/12/2019
  • Site web du projet : http://www.labex-lipstic.fr/
  • Mots clés : Lipoprotéines;cancer;inflammation;prévention;traitement;ciblage thérapeutique

Résumé du projet

The LipSTIC LabEx consortium involves 17 supervising institutions and private partners. Governance is operative with a board, a steering committee and an international scientific advisory board. The LipSTIC LabEx aims at fighting against cancer and inflammatory diseases with uncovered medical requirements. Here, lipoproteins (natural nano-carriers) are considered beyond their known involvement in cholesterol transport and cardiovascular diseases. Main goals are: 1) to identify lipoprotein parameters as new risk markers of cancer and inflammatory diseases, 2) to develop more effective and better-tolerated treatments of cancer and inflammation through stabilization and vectorization of lipoprotein-associated drugs, 3) to set up an innovative strategy in preventing uncontrolled inflammatory response through the lipoprotein-mediated neutralization and elimination of bacterial endotoxins, 4) to explore new anti-cancer and anti-inflammatory treatments, and 5) to increase relationships between researchers, social and political institutions, and private companies. A business plan, set up with the Society for Acceleration of Technology Transfer “SATT Grand Est”, Inserm Transfert and the Vitagora competitiveness cluster has led to patent registrations and new services through business units and startups. The LipSTIC LabEx has also provided information for medical decision and health authorities. Finally, the LipSTIC project has linked researchers, medical doctors, patients and their relatives, and the general public. In conclusion, the Investment for the Future Program (PIA) has constituted a unique opportunity to set up the innovative LipSTIC network taking advantage of scientific originality and efficient management to increase excellence and leadership, to interact with other PIA projects, to establish new teaching programs, to transfer results and knowledge to companies, services and society. Next challenge is to allow LipSTIC LabEx development beyond 2019.

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)